The Assessment of Background Parenchymal Enhancement (BPE) in a High-Risk Population: What Causes BPE?

You, Chao; Kaiser, Anna; Baltzer, Pascal; Krammer, Julia; Gu, Yajia; Peng, Weijun; Schönberg, Stefan O.; Kaiser, Ch.

doi:10.1016/j.tranon.2017.12.006

Cited by 10 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One hypothesis is that mutations in the BRCA gene and its associated sites activate the hormone receptor negative subtype-specific pathway, and the oncogene mediates DNA replication stress, thus directly triggering and promoting tumour progression (22). In this study, the BRCA-positive group, especially the BRCA1 mutation carrier group, had a significantly higher number of triple-negative breast cancers, which is in line with previous literatures (4,6,7,23). The absence of oestrogen receptors and progesterone receptors may lead to a decrease in BPE in BRCA mutation carriers.…”

Section: Discussionsupporting

confidence: 91%

The clinicopathological and MRI features of patients with BRCA1/2 mutations in familial breast cancer

You¹,

Xiao²,

Zhu³

et al. 2021

Gland Surg

Self Cite

View full text Add to dashboard Cite

Background: To determine the histopathological and MRI features of BRCA1/2 mutation-associated familial breast cancers compared with those of BRCA1/2 mutation-negative and sporadic breast cancers and to further compare the imaging features of cancers from BRCA1 and BRCA2 mutation carriers according to lesion type on MRI.Methods: A retrospective review of medical records was conducted to determine tumour clinicopathologic features and MRI characteristics between June 2011 and July 2017, and 93 lesions with BRCA mutations, 93 lesions without BRCA mutations from familial breast cancers and 93 lesions from sporadic breast cancers were included. Histopathologic data, including immunohistochemistry findings and MRI data according to the BI-RADS lexicon, were reviewed. The association between MRI or histopathologic findings and BRCA mutations was analysed.Results: BRCA-positive familial breast cancers had a higher number of IDCs with high nuclear grade and lymph node metastasis (all P<0.05), while the BRCA-negative group had a significantly lower Ki-67 index (P<0.001). BPE on MRI was found to be significantly lower for BRCA mutations of familial breast cancer (P=0.024). BRCA1 carriers tended to exhibit the triple-negative phenotype with a more benign shape and margin (P=0.006 and 0.019), whereas BRCA2 mutations were associated with the luminal phenotype and more malignant features.Conclusions: BRCA mutation carriers had a significantly higher number of IDCs with more aggressive cancer, and BRCA-negative cancers had low proliferation levels. Background features on MRI may help to identify BRCA status, while tumour characteristics can differentiate the BRCA1/2 mutation status, consistent with the differences in their clinicopathologic features.

show abstract

Section: Discussionsupporting

confidence: 91%

The clinicopathological and MRI features of patients with BRCA1/2 mutations in familial breast cancer

You¹,

Xiao²,

Zhu³

et al. 2021

Gland Surg

Self Cite

View full text Add to dashboard Cite

show abstract

“…In fact, there was only moderate correlation between quantitative and visual evaluation. This is certainly explained by the significant inter-observer variability of the 4-grade visual assessment, the presence of motion-induced artifacts (as the visual evaluation was done on subtracted uncorrected series) 28 as well as the difficulty to visually assess BPE in mainly fatty breasts.…”

Section: Discussionmentioning

confidence: 99%

Quantitative background parenchymal enhancement to predict recurrence after neoadjuvant chemotherapy for breast cancer

Molière

Oddou

Noblet

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Breast background parenchymal enhancement (BPE) is an increasingly studied MRI parameter that reflects the microvasculature of normal breast tissue, which has been shown to change during neoadjuvant chemotherapy (NAC) for breast cancer. We aimed at evaluating the BPE in patients undergoing NAC and its prognostic value to predict recurrence. MRI BPE was visually and quantitatively evaluated before and after NAC in a retrospective cohort of 102 women with unilateral biopsy-proven invasive breast cancer. Pre-therapeutic BPE was not predictive of pathological response or recurrence. Quantitative post-therapeutic BPE was significantly decreased compared to pre-therapeutic value. Post-therapeutic quantitative BPE significantly predicted recurrence (HR = 6.38 (0.71, 12.06), p < 0.05).

show abstract

“…Background parenchymal enhancement is a normal breast tissue enhancement on MRI [ 21 ]. Leddy has reported that moderate and marked BPE, which is difficult to differentiate from non-mass enhancement, is a cause of incorrect determinations and it is a diagnostic limitation of MRI [ 7 ].…”

Section: Discussionmentioning

confidence: 99%

Tumor size estimation of the breast cancer molecular subtypes using imaging techniques

Sezgin

Apaydin

Etıt

et al. 2020

Medicine and Pharmacy Reports

View full text Add to dashboard Cite

Background and aim. In medical practice the classification of breast cancer is most commonly based on the molecular subtypes, in order to predict the disease prognosis, avoid over-treatment, and provide individualized cancer management. Tumor size is a major determiner of treatment planning, acting on the decision-making process, whether to perform breast surgery or administer neoadjuvant chemotherapy. Imaging methods play a key role in determining the tumor size in breast cancers at the time of the diagnosis. We aimed to compare the radiologically determined tumor sizes with the corresponding pathologically determined tumor sizes of breast cancer at the time of the diagnosis, in correlation with the molecular subtypes. Methods. Ninety-one patients with primary invasive breast cancer were evaluated. The main molecular subtypes were luminal A, luminal B, HER-2 positive, and triple-negative. The Bland–Altman plot was used for presenting the limits of agreement between the radiologically and the pathologically determined tumor sizes by the molecular subtypes. Results. A significantly proportional underestimation was found for the luminal A subtype, especially for large tumors. The p-values for the magnetic resonance imaging, mammography, and ultrasonography were 0.020, 0.030, and <0.001, respectively. No statistically significant differences were observed among the radiologic modalities in determining the tumor size in the remaining molecular subtypes (p > 0.05). Conclusion. The radiologically determined tumor size was significantly smaller than the pathologically determined tumor size in the luminal A subtype of breast cancers when measured with all three imaging modalities. The differences were more prominent with ultrasonography and mammography. The underestimation rate increases as the tumor gets larger.

show abstract

The Assessment of Background Parenchymal Enhancement (BPE) in a High-Risk Population: What Causes BPE?

Cited by 10 publications

References 27 publications

The clinicopathological and MRI features of patients with BRCA1/2 mutations in familial breast cancer

The clinicopathological and MRI features of patients with BRCA1/2 mutations in familial breast cancer

Quantitative background parenchymal enhancement to predict recurrence after neoadjuvant chemotherapy for breast cancer

Tumor size estimation of the breast cancer molecular subtypes using imaging techniques

Contact Info

Product

Resources

About